Tikcro Technologies Reports 2010 Fourth Quarter Results

TEL AVIV, Israel--(BUSINESS WIRE)-- Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the fourth quarter and year ended December 31, 2010.

Net loss for the fourth quarter was $653,000 or $(0.08) per diluted share. Results for the fourth quarter included financial expenses of approximately $569,000 that resulted from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Excluding this non cash financial expense, net loss for the fourth quarter was $84,000 or $(0.01) per diluted share.

Net loss for the year ended December 31, 2010 was $778,000 or $(0.09) per diluted share. Results for the year ended December 31, 2010 included financial expenses of approximately $478,000 from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc. Excluding this non cash financial expense, net loss for the year ended December 31, 2010 was $300,000 or $(0.04) per diluted share.

Biocancell is a clinical stage biotechnology company focused on developing targeted cancer therapies for solid cancer tumors. The Company’s lead pipeline drug-candidate, BC-819, is progressing toward a US FDA Phase IIb clinical trial for pancreatic cancer. The Phase IIb clinical trial follows recently published one-year, multi-center Phase I/IIa results, addressing patients with non-resectable (inoperable) pancreatic cancer, with no metastases.

Following three months of treatment with BC-819 in the Phase I/IIa trial, five out of nine patients showed significant tumor reduction or stability, and two out of five of patients in the higher dosage group became resectable (operable).

Approximately 80% of patients with pancreatic cancer die within a year of diagnosis and 95% within five years. BC-819 uses the H19 gene to synthesize Diphtheria Toxin in cancerous cells only, in order to destroy the cells. BC-819 is also undergoing Phase IIb testing for bladder cancer and Phase I/IIa testing for ovarian cancer.

Tikcro holds approximately 25% of Biocancell, taking into account the conversion of a convertible note and exercise of warrants, and approximately 17% on a fully diluted basis. Shares of Biocancell are traded on the Tel Aviv Stock Exchange (TASE). The valuation of the holding in Biocancell is influenced, among other factors, by the share price of Biocancell on TASE.

As of December 31, 2010, the Company had net cash and marketable securities totaling $7.3 million.

"Tikcro intends to continue its strategy of providing funding for early-stage biotech operations, with an emphasis on solutions for the oncology market,” stated Aviv Boim, Tikcro’s CEO.

About Tikcro Technologies:

Tikcro has holdings in Biocancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Biocancell's leading drug, BC-819, is a double stranded DNA plasmid construct that incorporates the gene for diphtheria toxin (DTA) under the regulation of the promoter sequence for H19 gene. Pursuant to U.S. FDA approved protocols, Biocancell is conducting the following clinical trials in Israel and in the U.S. using BC-819:

-Phase IIb clinical trial for the treatment of superficial bladder carcinoma cancer
-Phase I/IIa clinical trial for the treatment of pancreatic cancer – trial concluded.
-Phase I/IIa clinical trial for the treatment of ovarian cancer

For more information, visit Tikcro website at www.tikcro.com.

Safe Harbor Statement

Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the business of BioCancell, including, but not limited to, the development, testing, regulatory approval and commercialization of its products, its intellectual property rights, its funding, its competition, its exposure to lawsuits and its dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Form 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. We undertake no duty to update any forward-looking information.

Tikcro Technologies Ltd.
Balance Sheet
(US dollars in thousands)
     
December 31, December 31,
2010 2009
Assets

 

Current assets
Cash and short-term marketable securities $ 7,308 $ 7,432
Other receivables 118 49
Total current assets 7,426 7,481
 

Investment in Biocancell – stock, convertible note and
warrant

5,625 6,164
 
Total assets $ 13,051 $ 13,645
 
Liabilities and Shareholders' Equity
Current liabilities  
Other current liabilities $ 318 $ 280
 
Shareholders' equity 12,733 13,365
 
Total liabilities and shareholders' equity $ 13,051 $ 13,645
 
Tikcro Technologies Ltd.
Statements of Operations
(US dollars in thousands, except per share data)
       
Three Months Ended December 31 Year Ended December 31

2010

2009

2010

2009

General and administrative expenses $140   $ 107   $ 389   $ 387  
 
Total operating expenses 140   107   389   387  
 
Operating loss (140 ) (107 ) (389 ) (387 )
 
Financial income (expenses), net (513 ) (1,705 ) (389 ) 3,282  
 
Net income (loss) $(653 ) $ (1,812 ) $ (778 ) $ 2,895  
       
Basic net earnings (loss) per share $(0.08 ) $ (0.22 ) $ (0.09 ) $ 0.35  
 
Diluted net earnings (loss) per share $(0.08 ) $ (0.22 ) $ (0.09 ) $

0.34

 
 
Basic weighted average shares 8,538   8,414   8,476   8,347  
 
Diluted weighted average shares 8,538   8,414   8,476  

8,392

 



CONTACT:

Investor Relations
KCSA Strategic Communications
Jeff Corbin / Marybeth Csaby
212-896-1214 / 1236
[email protected] / [email protected]

KEYWORDS:   Middle East  Israel

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.